iBio, Inc. (IBIO)

Last Closing Price: 0.75 (2026-11-17)

Company Description

Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $0.10M
Net Income (Most Recent Fiscal Year) $-33.04M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.58
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -3244.19%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -40.05%
Return on Assets (Trailing 12 Months) -35.35%
Current Ratio (Most Recent Fiscal Quarter) 9.48
Quick Ratio (Most Recent Fiscal Quarter) 9.48
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $1.12
Earnings per Share (Most Recent Fiscal Quarter) $-0.05
Earnings per Share (Most Recent Fiscal Year) $-0.27
Diluted Earnings per Share (Trailing 12 Months) $-0.28
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 70.46M
Free Float 69.36M
Market Capitalization $49.79M
Average Volume (Last 20 Days) 0.52M
Beta (Past 60 Months) 1.47
Percentage Held By Insiders (Latest Annual Proxy Report) 1.55%
Percentage Held By Institutions (Latest 13F Reports) 7.90%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%